Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Mesalamine Extended-Release Capsules USP, 0.375 g. In this regard, the company has enclosed a press release.
The above information is a part of company’s filings submitted to BSE.